[{"id":"a3752eca-3e48-4365-9dba-5171db569837","acronym":"","url":"https://clinicaltrials.gov/study/NCT02167854","created_at":"2021-01-18T10:05:49.948Z","updated_at":"2025-02-25T15:41:41.438Z","phase":"Phase 1","brief_title":"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT02167854","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 amplification • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Piqray (alpelisib) • elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/16/2014","start_date":" 06/16/2014","primary_txt":" Primary completion: 07/07/2021","primary_completion_date":" 07/07/2021","study_txt":" Completion: 07/07/2021","study_completion_date":" 07/07/2021","last_update_posted":"2021-07-09"},{"id":"25c037e9-0c80-4006-a0eb-eacdbbe10f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT01598077","created_at":"2021-01-18T06:49:57.264Z","updated_at":"2024-07-02T16:36:37.158Z","phase":"Phase 1","brief_title":"A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer","source_id_and_acronym":"NCT01598077","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2020-12-19"},{"id":"221ab4a7-e8a1-42f3-affc-34130424c231","acronym":"","url":"https://clinicaltrials.gov/study/NCT01911936","created_at":"2021-01-18T08:37:10.777Z","updated_at":"2024-07-02T16:36:37.216Z","phase":"Phase 1","brief_title":"A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01911936","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elgemtumab (LJM-716)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2020-12-17"}]